Cipla USA, Inc. recalls Nilotinib Capsules
FDA Class III
FDA classified this recall as Class III: the product is unlikely to cause health problems but breaks the agency's rules (a labeling mistake, for example).
- Hazard
- Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
- Products
-
- Nilotinib Capsules
- Company
- Cipla USA, Inc.
- Where it was sold
-
U.S.A. Nationwide
Nationwide
- Units affected
- 271 cartons - Ex: 84 outer cartons x 4 inner cartons x 4 blisters x 7 capsules
- About this recall
- Nilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each) NDC 69097-031-74; Inner carton: 28 capsules (4 blisters of 7 capsules) NDC 69097-031-56; Foil blister: NDC 69097-031-17